Still getting better as they speak: strength that has continued or built past the reported period, tied to named live dr
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that positive momentum has continued or strengthened beyond the reported period (Q4 2022) and ties that to a named, already-live driver. Let's examine the transcript. Management discusses Q4 results, challenges, and outlook for 2023. They mention that Q4 sales came in above low end of guidance, but overall revenue declined 10% year-over-year. They talk about challenges in physician office setting due to reimbursement uncertainty and competitive pressure. They mention bright spots: excluding certain products, they delivered low double-digit growth in accounts in hospital outpatient and physician office settings. They also mention double-digit growth in Advanced Wound Care in hospital outpatient setting. They talk about new product introductions. For 2023 guidance, they expect flat to 2% growth overall, with non-PuraPly products growing ~28% at midpoint. They mention that they expect to navigate continued challenges in office setting in 2023 due to competitive noise and uncertainty. They also mention that they have seen a pause in PuraPly XT acquisition after physician fee schedule dropped in mid-December. They say "our trends in 2023 so far are encouraging" in response to a question about competitive pressures. But is that a continuation of strength? The overall reported period is weak (revenue down 10%). They are not describing strong momentum continuing; they are describing a challenging environment with some bright spots. They mention that they expect growth in non-PuraPly products, but that's guidance, not observed activity beyond period. They also mention that they have seen encouraging trends in 2023 so far, but that is vague and not tied to a specific named driver? They mention new product launches, but they are not explicitly saying that the strength is continuing beyond the period in a concrete way. The question asks: "Does management convey that the business's positive momentum HAS CONTINUED OR STRENGTHENED BEYOND THE PERIOD BEING REPORTED — that the improvement did not stop when the quarter closed, but is still running at the time management is speaking — AND does management tie that continuing strength to at least one NAMED, ALREADY-LIVE driver of the business rather than to hopes about conditions?" The reported period is Q4 2022, which had a 10% decline in revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| CW | Curtiss-Wright Corporation | Q1 2024 | 2024-05-02 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CNA | CNA Financial Corporation | Q4 2022 | 2023-02-06 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| WHF | WhiteHorse Finance, Inc. | Q1 2022 | 2022-05-10 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| NGVT | Ingevity Corporation | Q4 2021 | 2022-02-25 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| PRI | Primerica, Inc. | Q3 2016 | 2016-11-10 | B+ |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
GES · Q1 2017 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the period being reported, tied to a named, already-live driver. YES Management describes continued strength in Europe retail comps into Q2 ("up in the low double digits... maintaining the strong momentum we have seen since the second half of last year") and ties it to a specific, live driver: improved traffic and conversion rates. The wholesale order book also finished up 3%, confirming 3% growth in orders already placed. Product improvements are explicitly named as the underlying driver ("we are having a more comprehensive collection... improve our comps by generating more traffic... improve the product that we are offering"). This meets both criteria for continuation beyond the reported period tied to a named live driver.
ILMN · Q1 2018 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the reported period, tied to a named, already-live driver. YES Management describes the sequencing consumables business as having "very exciting" trajectory and "tremendous momentum" that is "still in place" into the rest of 2018, explicitly tied to observed drivers already generating revenue in Q1 (NovaSeq, NextSeq, microarray, consumer genomics, oncology) and 2018 activity such as "approaching 100 orders" for iSeq and "growing interest" in single-cell research. They raise guidance based on these continuing trends rather than forecasts alone, confirming the strength has extended past the reported period through live business activity.
WRB · Q1 2022 → YESThe question is: Does management convey that the business's positive momentum HAS CONTINUED OR STRENGTHENED BEYOND THE PERIOD BEING REPORTED, and tie that to at least one NAMED, ALREADY-LIVE driver? ...NO The transcript shows management expressing confidence in Q1 momentum (especially March and later-quarter submissions in specialty/E&S) and noting that "every day that we are writing business in 2022 that goes by" is positive, but this is framed as ongoing daily activity within the current year rather than observed strength beyond the 2022 Q1 close. The call is April 25, 2022, so any post-quarter commentary is limited to general market trajectory comments without specific post-period-end activity metrics.